ASXL1 and hematopoietic and lymphoid cell neoplasm: ARCH/CHIP is mainly associated with mutations in three epigenetic regulatory genes—DNMT3A, TET2, and ASXL1—that have been implicated in hematologic cancers and is a strong risk factor for subsequent hematological cancers [69] (Fig. 2a).